News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • CNTB develops rademikibart to deliver rapid lung-function gains in acute asthma and COPD exacerbations.
  • CNTB market cap ~ $138.5M, shares trade near $2.20 after a $20.2M placement.
  • Company reports about $46M cash on the balance sheet.
  • Upcoming clinical readouts will determine whether rademikibart differentiates from Dupixent.
  • The setup is a binary, high-volatility swing trade; size positions accordingly.
  • Positive readouts could materially re-rate the stock, while negative results would likely cause sharp downside.

Latest Articles

Anixa Biosciences CEO Purchases $15,200 in Shares Amid Clinical Milestones

Anixa Biosciences CEO Purchases $15,200 in Shares Amid Clinical Milestones

Anixa Biosciences CEO Amit Kumar acquired 5,000 shares at $3.04 per share on July 10, 2026, increasing his direct holdings to 635,812 shares. The transaction coincides with the company's clinical trial milestones and the grant of a South Korean patent for its breast cancer vaccine technology. Despite recent progress, the company reported a net loss…

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy

Artelo Biosciences announced encouraging nonclinical findings for ART27.13, a peripheral cannabinoid receptor agonist, showing efficacy in reducing paclitaxel-induced neuropathic pain in animal models. This builds on interim Phase 2 CAReS trial results demonstrating improved body weight, lean mass, and activity in cancer patients with anorexia-cach…

Insider Transactions: Major Buys and Sells Reported Friday

Insider Transactions: Major Buys and Sells Reported Friday

Executives and significant shareholders disclosed several large equity purchases and sales across technology, cybersecurity, energy and industrial supply firms. Notable insider buys included large stakes in Netskope Inc, Big Digital Energy, Mission Produce and Gloo Holdings, while big sell-offs were reported at Broadcom, Dell Technologies, Okta, PB…

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics presented late-breaking Phase 2 clinical data of CAD-1005, a first-in-class 12-lipoxygenase inhibitor targeting Heparin-Induced Thrombocytopenia (HIT), at the ISTH 2026 Congress. The randomized, placebo-controlled trial demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo, with a favorabl…

RedCloud unveils CORE, the Operating Environment That Will Unify Trade Intelligence and Action, Built on $6.9 Billion Data Foundation

RedCloud unveils CORE, the Operating Environment That Will Unify Trade Intelligence and Action, Built on $6.9 Billion Data Foundation

RedCloud Holdings plc announced CORE, its new trade execution engine and central component of the RedAI infrastructure, designed to automate trade actions using AI within the global FMCG sector. CORE, alongside RAID, leverages a proprietary $6.9 billion data foundation and aims to bridge the gap between AI recommendations and automated trade execut…

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics Biotech reported strong clinical progress and a regulatory milestone for its REO 033 randomized trial evaluating pelareorep in combination with chemotherapy for second-line treatment of RAS-mutant microsatellite stable metastatic colorectal cancer. The company plans a Type D meeting with the FDA to discuss a registrational path by adding…

Workhorse Appoints Jody Davis as Chief Financial Officer

Workhorse Appoints Jody Davis as Chief Financial Officer

Workhorse Group Inc., a US-based electric vehicle manufacturer specializing in medium-duty trucks, announced the appointment of Jody Davis as its new Chief Financial Officer. Davis brings 15 years of finance leadership experience from sectors including manufacturing and energy storage, and is expected to support Workhorse's transition from developm…

T3 Defense Subsidiary Rimon Delivers $1.1 Million Order with Major Israeli Defense Customer for Advanced Elevated Battlefield Lighting Systems

T3 Defense Subsidiary Rimon Delivers $1.1 Million Order with Major Israeli Defense Customer for Advanced Elevated Battlefield Lighting Systems

T3 Defense's subsidiary Rimon completed the delivery of a $1.1 million order of Yam-Or portable elevated lighting systems to a major Israeli defense customer. The order was fulfilled on schedule and adhered to stringent defense specifications, highlighting Rimon's engineering and manufacturing capabilities for advanced battlefield illumination solu…

Power Solutions International Sets Date for Second Quarter 2026 Earnings Release and Conference Call

Power Solutions International Sets Date for Second Quarter 2026 Earnings Release and Conference Call

Power Solutions International, Inc. (NASDAQ: PSIX), a designer and manufacturer of emission-certified engines and power systems, will release its second quarter 2026 earnings on August 6, 2026, followed by a conference call to discuss financial results and business outlook. The company serves diverse markets including power generation, industrial e…

SoundHound AI Named a Leader in the 2026 Gartner® Magic Quadrant™ for Conversational AI Platforms

SoundHound AI Named a Leader in the 2026 Gartner® Magic Quadrant™ for Conversational AI Platforms

SoundHound AI, Inc. has been named a Leader in the 2026 Gartner Magic Quadrant for Conversational AI Platforms. Its Amelia 7 conversational AI platform, known for voice-native design and advanced multi-intent capabilities, has gained strong enterprise adoption. The company expanded its market presence with strategic acquisitions and launched OASYS,…

Deckers: Cash, Category Share, and a Clear Path Higher

Deckers: Cash, Category Share, and a Clear Path Higher

Deckers (DECK) is trading at a reasonable multiple, sitting on strong free cash flow and benefiting from durable brand momentum at HOKA and UGG. With Nike's execution problems leaving openings in running and lifestyle categories, Deckers can accelerate share gains. This is a swing trade idea to capture continued top-line and margin leverage over th…

Premier Urges Stronger Counter-Cyclical Measures as Growth Momentum Slows

Premier Urges Stronger Counter-Cyclical Measures as Growth Momentum Slows

Chinese Premier Li Qiang urged a broader, objective appraisal of the country’s economic condition and called for stepped-up counter-cyclical policy adjustments to bolster momentum as signs point to slowing growth. His remarks, delivered at a meeting with experts and entrepreneurs and reported by state broadcaster CCTV, come ahead of the government'…